Clinical trials recruiting in Drammen, Norway

Phase breakdown

Conditions recruiting in Drammen, Norway

Recruiting trials in Drammen, Norway

• 18F-FDG PET/CT Imaging for Breast Cancer
  NCT05730608 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  NCT06119581 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
  NCT06077760 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
  NCT06227910 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  NCT06312137 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
  NCT07063745 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Biology of Juvenile Myoclonic Epilepsy
  NCT03400371 · Phase: Not specified · Ages: 10 Years to 40 Years · Sex: All (male and female)
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression
  NCT07312110 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• DESTINY Breast Respond HER2-(Ultra)Low Europe
  NCT05945732 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
  NCT06395883 · Phase: Not specified · Ages: 25 Years to 90 Years · Sex: All (male and female)
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
  NCT06197048 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• INTEgRated Health CARE for Patients With Frailty and Heart Failure
  NCT06444321 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Imaging Treat-to-target Strategy vs Conventional Treat-to-target Strategy in Psoriatic Arthritis
  NCT05291819 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer
  NCT05448547 · Phase: Phase 3 · Ages: 75 Years and older · Sex: Male
• Management of Patients With Heart Failure at Home After Hospital Discharge
  NCT06576752 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  NCT04613596 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  NCT06393374 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
  NCT06697301 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
  NCT07100080 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
  NCT06890598 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
  NCT06801834 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The Norwegian Antirheumatic Drug Register
  NCT01581294 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• The PEDAL Intervention - Reducing Affective Lability in Bipolar Disorder
  NCT07239778 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Thrombolysis in Factor Xa-inhibitors Trial
  NCT06878066 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Wrist and Carpal Arthrodeses. A 1-year Follow-up Study.
  NCT06917235 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Drammen, Norway?

30 recruiting trials have at least one study site in Drammen, Norway.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.